A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan

Kinya Okada,Yoshikazu Nakayama,Jennings Xu,Yang Cheng,Junko Tanaka
DOI: https://doi.org/10.1111/hepr.14056
2024-05-17
Hepatology Research
Abstract:The real‐world data study using an electronic medical record database revealed that hepatitis B surface antigen seroclearance and low baseline hepatitis B surface antigen level are valuable for long‐term outcomes of patients with chronic hepatitis B virus infection in the Japanese population. Aim Hepatitis B surface antigen (HBsAg) seroclearance is considered to be one of the best surrogate endpoints of functional cure for hepatitis B virus (HBV) infection. However, evidence regarding the relationship between achieving HBsAg seroclearance or a low baseline HBsAg level, and long‐term clinical outcomes in Japanese patients with chronic HBV infection remains to be confirmed in a real‐world setting. Methods A retrospective observational cohort study was performed with an electronic medical record database, including data from 230 hospitals across Japan. Chronic HBV infection was defined as two consecutive, positive HBsAg laboratory measurements for HBV infection. The date of the second positive was used as a baseline to identify subsequent HBsAg seroclearance and liver disease progression. Results In the database, 2523 patients with chronic HBV infection were identified as the chronic hepatitis B (CHB) cohort. Among the CHB cohort with an average observational period of 5.19 ± 3.87 years, 202 patients (8%) achieved HBsAg seroclearance after baseline. They had a lower risk of developing hepatocellular carcinoma (HCC) (adjusted hazard ratio [aHR] 0.206, p
gastroenterology & hepatology
What problem does this paper attempt to address?